2026-10-08

Viatris Buys Pacira BioSciences for $1.65 Billion - EXPAREL and ZILRETTA Complete a Non-Opioid Pain Portfolio

Written & reviewed by the TradeSmrt editorial team · 2026-10-08

In this article

What Happened
Why Viatris Is Moving Into Pain Management Now
What to Take Away From This
FAQ
Sources

What Happened

On Thursday, October 8, generics and off-patent brand giant Viatris (NASDAQ: VTRS) announced a definitive agreement to acquire Pacira BioSciences (NASDAQ: PCRX), a company focused on non-opioid pain management. The deal values Pacira at $36.50 per share in cash, for a total equity value of approximately $1.65 billion. Structurally, Viatris will launch a tender offer for Pacira's outstanding shares first, then sweep up any remaining shares through a second-step merger at the same price under Section 251(h) of Delaware corporate law - a provision that lets an acquirer skip a separate shareholder vote once the tender offer clears a majority threshold. Both companies expect the deal to close by the end of 2026, and say it will be immediately accretive to Viatris's financial guidance metrics once it does.

Pacira's business centers on two non-opioid pain products. The first, EXPAREL (bupivacaine liposome injectable suspension), is used to manage acute, localized pain after surgery. The second, ZILRETTA (triamcinolone acetonide extended-release injectable suspension), is described as the only approved extended-release, intra-articular injection for managing osteoarthritis knee pain - Pacira added it to its pipeline through its 2021 acquisition of Flexion Therapeutics. For the twelve months ended June 30, 2026, Pacira reported roughly $746 million in total revenue and approximately $177 million in adjusted EBITDA.

Why Viatris Is Moving Into Pain Management Now

The key to understanding this deal is Viatris's own in-house pipeline asset: a fast-acting meloxicam program currently in development. Viatris CEO Scott Smith said directly in the announcement that EXPAREL (acute post-surgical pain) and ZILRETTA (chronic osteoarthritis knee pain) are synergistic with that meloxicam candidate. Line the three products up and the logic becomes clear: EXPAREL covers the acute period right after surgery, ZILRETTA covers chronic joint pain, and Viatris's meloxicam would sit in the middle ground between the two. Combined, they form a portfolio that spans a patient's pain-management journey from the immediate post-surgical period through longer-term chronic care. That matters because U.S. healthcare providers and payers have been pushing hard to reduce opioid prescriptions in favor of non-opioid alternatives, and Viatris appears to be positioning itself as a one-stop provider riding that shift.

A second detail worth flagging is Viatris's stated intent to "leverage its intellectual property expertise and its ability to extend product lifecycles." Viatris itself was formed in 2020 from the merger of Pfizer's off-patent branded drug unit (Upjohn) with generics specialist Mylan, and it has built its core competency around defending and monetizing branded drugs as patents expire and generic competition arrives. EXPAREL and ZILRETTA both currently enjoy patent-protected exclusivity windows that won't last forever, so Viatris is signaling confidence that it can apply its existing know-how - delaying generic or biosimilar entry and defending sales after exclusivity lapses - to these newly acquired assets as well. In other words, this isn't simply buying products that sell well today; it's applying a capability Viatris already has (extending the commercial life of off-patent assets) to a new set of products.

The deal's size also matters in context. At $1.65 billion, this is a relatively modest "bolt-on" acquisition for a company of Viatris's scale, which generates tens of billions of dollars in annual revenue. Yet management's explicit claim that the deal will be immediately accretive is a meaningful signal. M&A deals often dilute near-term profitability during integration, so a confident claim of immediate accretion suggests either that Pacira's margins (its adjusted EBITDA margin runs around 24% of revenue) compare favorably to Viatris's own average, or that Viatris is funding a meaningful portion of the purchase at a relatively low cost of capital.

What to Take Away From This

Look at the product combination an acquirer highlights as "synergistic" - it usually reveals the real strategy. How EXPAREL (acute pain) and ZILRETTA (chronic joint pain) fit alongside Viatris's meloxicam program shows this deal is a deliberate attempt to complete a portfolio, not simply a bolt-on for extra revenue.
When a company says a deal is "immediately accretive," check whether the price paid actually supports that claim. Comparing Pacira's trailing adjusted EBITDA ($177 million) to the purchase price ($1.65 billion) implies a valuation multiple of roughly 9x EBITDA; confidence in immediate accretion at that multiple can be a signal about Viatris's own funding cost or valuation multiple relative to the target.
A tender offer structured under Delaware's Section 251(h) is a classic way to speed up deal closing. Skipping a separate shareholder vote tends to shorten the timeline versus a traditional merger process, which also means target shareholders receive their cash sooner than they would under a longer process.
A "small" bolt-on acquisition by a large pharma company is rarely trivial for the target - or meaningless for the acquirer's trajectory. $1.65 billion barely moves the needle for Viatris as a whole, but it's a company-defining event for Pacira, and a string of similarly sized deals can gradually reshape a large pharma's overall portfolio direction.
M&A activity keeps confirming the structural growth story around non-opioid pain alternatives. The non-opioid pain market benefits from a long-running regulatory and payer tailwind, and continued acquisitions of assets like these are a sign that conviction in that theme remains intact across the industry.

FAQ

What should Pacira shareholders do right now?

Viatris will first run a tender offer, typically open for at least 10 business days (extendable). Shareholders who don't tender will still receive the same $36.50 per share in cash through the subsequent second-step merger, assuming the deal closes as planned - meaning all shareholders ultimately receive the same price. Regulatory review and other closing conditions remain outstanding until the deal is finalized, though.

What conditions do ZILRETTA and EXPAREL treat, specifically?

EXPAREL is a liposomal (lipid-encapsulated) bupivacaine injection used to manage acute, localized pain immediately following surgery. ZILRETTA is an extended-release (slow-release) triamcinolone formulation injected directly into the joint to manage osteoarthritis knee pain, and it's described as the only approved product of its kind - an extended-release intra-articular injection for that indication.

What does this mean for Viatris's stock?

Because management has stated the deal will be immediately accretive upon closing, it's viewed as a financially low-risk transaction for Viatris. That said, since $1.65 billion is small relative to Viatris's overall market capitalization, the stock impact is likely to be far less dramatic than the premium effect Pacira's own shareholders are receiving.

Sources

This article is an original synthesis and analysis based on the reporting below, not a reproduction of the original articles. Please check the source articles directly for the most current figures.

⚠️ This article is for informational purposes only and is not investment advice. Market conditions change constantly - always verify the latest data before making investment decisions.